Investigational drug · Phase 2
Londamocitinib
Also called: AZD4604
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Asthma.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 13, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
1
Any phase or sponsor naming "Londamocitinib"
First trial start
2023
Nov 16, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Londamocitinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Asthma
Approved drugs for the same conditions: Asthma · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "Londamocitinib" as an intervention, largest first.
AstraZenecaAstraZeneca (AZN)
NCT06435273 · 36 participants · Start Aug 5, 2024 · Primary completion Oct 15, 2025
Drug: AZD4604; Placebo to AZD4604 · For: Asthma
Sites: Calgary, Canada; Vancouver, Canada; Montreal, Canada · 18 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Absorption, distribution, metabolism and excretion of londamocitinib after single-dose inhaled, intravenous and oral administration in healthy participants.
Riff C, Bold P, Heijer M, et al. · Br J Clin Pharmacol 2026
- Iron-Catalyzed Ligand-to-Metal Charge Transfer (LMCT) Desulfonylation of Sulfonamides under Visible Light.
Cao MY, An BH, Lü S, et al. · Org Lett 2026
- First-in-human study for londamocitinib (AZD4604), an inhaled selective JAK1 inhibitor.
Jellesmark Jensen T, Riff C, Lund J, et al. · J Allergy Clin Immunol 2026
- Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABA.
Mustapa MN, Hughes R, Jensen TJ, et al. · BMJ Open Respir Res 2026
- ARTEMISIA: a mechanistic study of a novel Janus kinase 1 inhibitor to advance molecular understanding and precision medicine in asthma.
Dosanjh DPS, Darrah E, Jensen TJ, et al. · Respir Res 2025
- Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization.
Nilsson M, Berggren K, Berglund S, et al. · J Med Chem 2023
Also in development for Asthma
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.